NCT02792465View on ClinicalTrials.gov

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 11, 2016

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Advanced Solid CancersBreast Cancer
Interventions
DRUG

CFI-402257

DRUG

Fulvestrant

Trial Locations (3)

V5Z 4E6

BC Cancer Agency, Vancouver

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER